

Dr Rahul Kushwah on how Predictmedix's AI driven Safe Entry Station detects disease and impairment symptoms

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about Predictmedix's artificial intelligence powered infectious disease symptom screening solution for workplace health and safety.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to say, "You can open facilities and workplaces but it is about bringing in technologies that can create safety bubbles in those places. That is where our infectious disease symptom screening solution or Safe Entry Station comes into play. The technology can identify a host of symptoms associated with COVID-19."

Speaking on the competitive advantages of Predictmedix's Safe Entry Station Dr. Kushwah said, "It looks at several symptoms associated with infectious diseases. So, it is not just another fever scanner. At the same time, there is a deep learning algorithm that runs in the background. **As more and more people pass through the system the system keeps on getting smarter.**"

To watch the full interview, click here

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and

alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease.

To learn more about Predictmedix Inc., [click here](#)

Disclaimer: *Predictmedix Inc. is an advertorial member of InvestorIntel Corp.*

Dr Rahul Kushwah on infectious disease symptom screening technology, sales and the Predictmedix partnerships in play

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) about ramping up their sales and business development efforts and provides an update on partnerships already in play.

Predictmedix is dedicated to health and wellness using artificial intelligence powered technologies. In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Dr. Kushwah went on to provide an update on the Safe Entry Stations powered by Predictmedix's proprietary infectious disease symptom screening technology. "We have had successful deployment with several companies including Fortune 500 companies such as Indian Oil," Dr. Kushwah said.

Predictmedix has been actively signing partnerships with some of the major healthcare providers. "We have partnered with Max Healthcare which is one of the largest groups of hospitals in Asia...At the same time we have just deployed our technology at MGM Hospital in Mumbai and that is one of the largest COVID-19 clinics in India."

To watch the full interview, click here

About Predictmedix Inc.

Predictmedix Inc. is an artificial intelligence ("AI") company

developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.

The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.

Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease.

To learn more about Predictmedix Inc., [click here](#)

Disclaimer: *Predictmedix Inc. is an advertorial member of InvestorIntel Corp.*

Safe Entry Stations offers real competition in the AI-driven remote sensing reality already for entry

“Hey Siri”

“Hey Google”

“Hey Alexa”

Have we missed anybody? Probably... Yes, technology is watching you, but is that a good or a bad thing?

In the case of Predictmedix Inc. (CSE: PMED) (OTCQB: PMEDF), that's the point and yes it is a good thing. As some of you know, the company “develops disruptive AI technologies for health and safety in workplaces and healthcare”. Translated – ***remote sensing and artificial intelligence (AI) solutions to protect our health.***

The value of this technology should not be underestimated, necessity is the mother of invention. It's a coronavirus world now and the virus (like the flu, like a cold etc.) isn't going away anytime soon. The arrival of the virus and the global pandemic that followed means that there is now a serious focus on detection of early indicators of infected people. Detection will help stem the spread of the coronavirus and others.

Predictmedix is one of those companies which has an infectious disease screening solution. However, unlike the competitors, the company's Safe Entry Station is head and shoulders above the competition. The fact that the company has Kapil Raval as its Advisory Board Chair should tell the market something – he is the Director of AI, Business Development, for Microsoft.

“Having a long-term sustainable product for better workplace health and safety” is how Dr. Rahul Kushwah, company COO described their vision. Their screening solutions are powered by AI and are designed to analyze seven different symptoms associated with the coronavirus, providing results in seconds. The system utilizes multispectral imaging with a focus on visual spectral imaging along with infrared thermography to identify individuals exhibiting symptoms associated with infectious diseases. The coronavirus detection system is commercial and is being deployed now.

The AI monitors and identifies potential presence of infectious disease symptoms such as fatigue, headache, coughing, sneezing, blood flow, sweat gland activation, metabolism, fever along with other key determinant factors. Sick or not sick.

The AI algorithms in their system are also continuously evolving via machine learning and should be able to detect, assess and determine the probability of that person being infected or not infected, even as the virus mutates. Sick or not sick.

So significant is this technology that the company already has partnerships in Canada, the US and India for system installation. A very significant customer is Indian Oil Corporation (IOC), where deployment is at the logistics stage – IOC has a workforce of more than 33,000 employees. There are several other deployments in the planning stage yet to be announced.

With a physical detection system, in addition to assessing virus conditions, the company can also utilize the AI for the detection of alcohol, cannabis and opioid intoxication. The company has a first-to-market cannabis AI detection system which is being expanded to analyze for other intoxicants. The system uses multispectral recognition technologies that capture data analyzed by the proprietary AI. This is

especially important in environments where impairment could be considered a safety risk.

Lastly, a third use for AI detection technology relates to the detection of psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease, all of which may benefit the individual when detected early. With an aging population, this could be a massive market and for anyone with loved ones who suffer from any of these disorders, you know the importance of early detection.

In keeping with the company's screening focus, in 2020 Predictmedix acquired Mobile Wellbeing, a telemedicine remote patient monitoring platform that will integrate with Predictmedix's AI driven rapid screening system for infectious diseases. According to the company, Mobile Wellbeing has demonstrated its value in multiple different programs over several years, and has shown benefits such as improved patient health, minimized the impact of chronic disease, and driven down the cost for care through remote monitoring.

With an inherent demand for quick, effective and non-invasive detection technologies, Predictmedix is in a very desirable market with an industry leading product. While the company share price has fallen dramatically from the July 2020 high of \$1.13, watch for significant business progress and announcements that could reverse this share price trajectory. The Safe Entry System (and others like it) are soon going to become as common as automatic door openers and could be deployed anywhere there is a large movement of people. The market potential is huge – don't miss it!

Punching above their weight, Predictmedix keeps nailing the heavyweight health tech partnerships

As the world shifts to a “new” normal, employee and customer screenings will be commonplace and Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) and its solutions are leading the way.

The recent announcement by Predictmedix, regarding the partnership with McGill University, is another example of the relationships that Dr. Rahul Kushwah, COO of Predictmedix, is developing with major corporations and leading healthcare providers as it rolls out Artificial Intelligence (“AI”) health tech solutions.

Predictmedix aims to improve the healthcare system through innovative and cutting-edge digital health technologies. Currently, Predictmedix AI solutions focus on infectious-disease screenings, impairment detection, and remote patient monitoring.

The Company’s products use facial, thermal, video, and audio recognition technologies to determine when individuals are impaired, suffering from an infectious disease, or mental illness. One solution focuses on mass and rapid AI-based screening for COVID-19 symptoms.

Partnerships, Pilots, Trials and Installs – Where Does Predictmedix Find the Time

Earlier this month, Predictmedix announced partnering with a research group led by Dr. Samira Rahimi from McGill University’s Department of Family Medicine.

Dr. Rahimi's research group will be working with Predictmedix and its three industry verticals: (1) screening for infectious disease associated symptoms; (2) screening for alcohol or cannabis impairment; and, (3) mental health screening.

Dr. Rahul Kushwah commented, "We are extremely excited with the partnership with Dr. Samira Rahimi's team. Dr. Rahimi is one of the most recognized AI – healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals."

The announcement with McGill is just the latest in a series of pilot projects, partnerships, and product rollouts that Predictmedix has successfully executed this year. Predictmedix believes that it is well-positioned for growth and to capture the current sales momentum into Q1/2021.

Recently, the Company announced that it will be deploying its COVID-19 screening technology along with alcohol and impairment screening technology at Indian Oil Corporation Ltd (NSE:IOC.NS), a multi-billion dollar India-based oil company, and the deployment of its mass screening technology for COVID-19 with Max Healthcare, one of the largest healthcare groups in South Asia, encompassing 14 hospitals with over 3000 doctors.

Predictmedix also announced a collaboration with India-tech giant Tech Mahindra Ltd (NSE: TECHM), to incorporate Predictmedix's impairment detection technology and COVID-19 solutions into Tech Mahindra's suite of technologies offered for workplace health and safety across the globe.

Closer to home, the Company, in conjunction with its partner Juiceworks Exhibits, successfully deployed its infectious disease screening technology at Flow Water in Aurora, Ontario, and a 24-hour pharmacy in Montreal, Quebec.

Used by employees on a daily basis, Predictmedix's gateway

screens individuals, in a non-invasive way, as they walk through and it triggers an alarm if symptoms associated with an infectious disease are detected, such as COVID-19, or signs of impairment due to alcohol or cannabis use.

The screening product consists of hardware, software, multi-spectral cameras, and specialized sensors that are assembled into a gateway, much like a metal detector in an airport, and communicates with Predictmedix's AI model in the cloud.

Remote Patient Monitoring & Telehealth Enterprise Platform with Mobile Wellbeing Acquisition

In June, Predictmedix acquired Mobile Wellbeing, a remote patient monitoring platform, which is strategic for the Company in creating an enterprise platform and allows Predictmedix to enter the telehealth and clinical trials markets.

According to a recent by study Adroit Market Research, the Remote Patient Monitoring Market is anticipated to reach US\$1.9 billion by 2026, growing at a CAGR of almost 13% from 2020 to 2026.

With current stay-at-home orders due to the COVID-19 health crisis, clinical drug trials shifted to remote monitoring from on-site monitoring. The U.S. Food and Drug Administration ("FDA") now supports remote monitoring for oversight of clinical sites.

In addition, the Mobile Wellbeing platform is equally suited for use in long-term care facilities to care for elderly patients. Big Data features include assisted monitoring that allows for data collection, transmission, evaluation, and notification. Utilizing the latest off-the-shelf wearables, the platform has shown benefits such as improved patient health and also lowered the cost of care through remote monitoring.

Predictmedix anticipates the commercial launch of its remote patient monitoring platform Q1/2021 with some key, large-scale deployments in North America and Asia.

Predictmedix is currently trading at \$0.46 with a market cap of \$46.5M but with billion-dollar partners and a pipeline of projects in Q1/2021, clearly ready for a re-rating.

Dr. Rahul Kushwah on Predictmedix's remote patient monitoring technology and Mobile Wellbeing

In a recent InvestorIntel interview, Tracy Weslosky speaks with Dr. Rahul Kushwah, Co-Founder and COO of Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF), about their infectious disease screening technology and remote patient monitoring platform, Mobile Wellbeing.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here to subscribe to the InvestorIntel Channel](#)), Dr. Kushwah talked about the successful North American deployment of Predictmedix's infectious disease screening technology at Flow Water in Aurora, Ontario. Dr. Kushwah went on to provide an update on their Mobile Wellbeing platform. "It is in telehealth and telemedicine business, but it does more than that." He continued, "It does something which is referred to as remote patient monitoring." Dr. Kushwah added that Predictmedix is targeting clinical trials and long-term care markets with its Mobile Wellbeing platform. FDA now has very strong guidance which is promoting remote

patient monitoring and that brings Predictmedix's technology to the forefront.

In the interview Dr. Kushwah also said that Accenture, a multinational professional services company and a Fortune Global 500 company, recently wrote about how Predictmedix is innovating to help with the current COVID-19 pandemic (click here to read the article). "It should indicate to shareholders that not only our technology is disruptive but we are clearly in a market segment which is not only ballooning right now but is going to be huge as time goes by." Dr. Kushwah commented. To watch the full interview, click here

About Predictmedix

Predictmedix develops AI technologies focused on areas which include screening for impairment, infectious disease and mental health, and a remote patient monitoring/telehealth platform, all of which play a vital role in health and safety. Their technologies are timely to assist with the current pandemic, as well as having lasting utility that goes beyond the current crisis, extending into workplace health, safety and compliance.

To learn more about Predictmedix Inc., click here

Disclaimer: Predictmedix Inc. is an advertorial member of InvestorIntel Corp.